Skip to content
AnalystLens

BridgeBio Pharma Annual Report, Year Ended Dec 31, 2020

Filing Date
Filed February 25, 2021
Period End
December 31, 2020
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Oct ’21Oct ’21
  3. Material agreement8-K · Sep ’23Sep ’23
  4. Material agreement8-K · Aug ’26Aug ’26

Summary

Summary of the 10-K filed February 25, 2021. Cited figures are marked; the original filing is the authoritative source.

BridgeBio Pharma, Inc. reported its 2020 annual results in this Form 10-K filed February 25, 2021.

The company is a clinical-stage biopharmaceutical company focused on Mendelian diseases and genetically driven cancers. It has not generated product revenue. License revenue was $8.2 milliona in 2020, down from $40.6 million in 2019.

Net loss was $505.5 millionb in 2020, compared with $288.6 million in 2019 and $169.5 million in 2018. The accumulated deficit reached $888.8 million at December 31, 2020. Research and development expense rose to $337.0 million and general and administrative expense to $145.7 million.

At year-end, cash, cash equivalents and marketable securities totaled $607.1 millionc, and the company stated that this would fund operations for at least the next 12 months. Total consolidated indebtedness was $642.5 million, including $550.0 million of 2.50% convertible senior notes due 2027.

In January 2021 the company completed its acquisition of Eidos Therapeutics, issued $717.5 milliond of 2.25% convertible notes due 2029, and reported that the 2029 notes generated net proceeds of approximately $731.7 million. Lead programs include acoramidis for ATTR cardiomyopathy, in a Phase 3 trial with top-line 6MWD data expected in late 2021 or early 2022; low-dose infigratinib for achondroplasia, with PROPEL 2 data expected in the second half of 2021; and infigratinib for cholangiocarcinoma, under an NDA with Priority Review.

Key Highlights

  1. No product revenue to date; 2020 license revenue of $8.2 million, mainly from an $8.0 million upfront payment from LianBio.
  2. Net loss of $505.5 million in 2020 (vs. $288.6 million in 2019); accumulated deficit of $888.8 million.
  3. Cash, cash equivalents and marketable securities of $607.1 million at December 31, 2020, expected to fund operations for at least the next 12 months.
  4. Total consolidated indebtedness of $642.5 million at year-end, including $550.0 million of 2.50% convertible notes due 2027.
  5. Eidos Merger closed January 26, 2021: $21.3 million cash plus about 26.1 million BridgeBio shares; a $717.5 million 2.25% convertible note offering followed on January 28, 2021.
  6. Core value drivers include acoramidis (Phase 3 ATTRibute-CM), low-dose infigratinib (Phase 2 PROPEL 2) and BBP-631 (planned Phase 1/2), with the infigratinib cholangiocarcinoma NDA under Priority Review.
  7. Company ceased to be an emerging growth company and became a large accelerated filer as of December 31, 2020; Deloitte & Touche issued an unqualified internal-control opinion.

Financial Statements

FY2020 against FY2019

Line itemFY2020FY2019Change
Revenue$8.25M$40.56M−79.7%
R&D Expenses$337.05M$209.95M+60.5%
SG&A Expenses$145.68M$94.35M+54.4%
Operating Expenses$482.73M$306.80M+57.3%
Operating Income-$474.48M-$266.24M−78.2%
Interest Expense$36.66M$8.77M+318.2%
Net Income-$448.72M-$260.59M−72.2%
EPS (Basic)$-3.80$-2.48−53.2%
EPS (Diluted)$-3.80——
Shares Outstanding (Basic)118.00M105.10M+12.3%
Shares Outstanding (Diluted)118.00M——

Frequently Asked Questions

  1. Does BridgeBio generate revenue from product sales?

    No. The filing states that BridgeBio has no products approved for commercial sale and has not generated revenue from product sales. Its 2020 license revenue of $8.2 million came primarily from an upfront payment from LianBio under a license agreement for BBP-398.

  2. How large are the company's losses and how are they trending?

    Net losses were $505.5 million in 2020, $288.6 million in 2019 and $169.5 million in 2018. Research and development expense increased to $337.0 million in 2020 from $209.947 million in 2019, and general and administrative expense increased to $145.7 million from $94.4 million. The company expects losses to increase substantially in future periods.

  3. How much liquidity does BridgeBio have and how much debt does it carry?

    At December 31, 2020 the company held $607.1 million in cash, cash equivalents and marketable securities and reported total consolidated indebtedness of $642.5 million. It said these resources should fund operations for at least the next 12 months, and that additional financing could be needed sooner if plans change.

  4. What are the near-term catalysts disclosed for investors?

    The filing expects top-line 12-month 6-minute walking distance data from Part A of the acoramidis ATTRibute-CM Phase 3 trial in late 2021 or early 2022, initial PROPEL 2 data for low-dose infigratinib in the second half of 2021, and initial BBP-631 Phase 1/2 data in late 2021 or early 2022. It also says the infigratinib cholangiocarcinoma NDA has Priority Review designation.

  5. What did the Eidos Merger involve?

    BridgeBio acquired all outstanding Eidos common stock not already owned, closing on January 26, 2021. Eidos holders could elect 1.85 BridgeBio shares or $73.26 in cash per share, subject to a $175.0 million cap on cash. The company said the transaction was settled through $21.3 million in cash and about 26.1 million shares of common stock, and total estimated transaction costs were $78.2 million.